Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Indivior (INDV)

Indivior completes U.S. domestication, with Indivior U.S. becoming the new parent company

Neutral Impact 4 of 5 restructuring Written later

Indivior, which the filing identifies as Indivior Pharmaceuticals, Inc., completed its change of domicile to the United States after the close of trading on January 23, 2026, making Indivior U.S. a Delaware company and the parent of Indivior PLC. The filing also covers an amendment to a note purchase agreement, new indemnification agreements, a 2026 equity plan, and officer and director details, which show how the company is governed after the change. Shareholders receive one share of Indivior U.S. common stock for each Indivior PLC ordinary share they held.

Key points

  • The scheme of arrangement became effective after the close of trading on January 23, 2026, and each Indivior PLC ordinary share was cancelled in exchange for one share of Indivior U.S. common stock, par value $0.001.
  • A First Amendment to the Note Purchase Agreement, dated January 21, 2026 and effective January 26, 2026, moves financial reporting to Indivior U.S. from Indivior U.K.
  • The Indivior U.S. 2026 Omnibus Equity Incentive Plan reserves 17,500,000 shares, and non-employee director pay is capped at $1,000,000 per fiscal year.
  • Joe Ciaffoni is listed as Chief Executive Officer and Ryan Preblick as Chief Financial Officer.

The filing

CompanyIndivior (INDV)
Form8-K, current report
Filed with the SECJan 26, 2026, 7:01 AM ET
Accession number0001193125-26-021660

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale3.03 Change to Shareholder Rights5.01 Change in Control5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.05 Code of Ethics Change7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.